Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / ADAM12

ADAM12

Basics

Aliases:
This biomarker is also known as:
  • MLTN,
  • a disintegrin and metalloproteinase domain 12 (meltrin alpha),
  • disintegrin and metalloproteinase domain-containing protein 12,
  • MCMP,
  • O43184,
  • MCMPMltna,
  • MLTNA,
  • Meltrin-alpha,
  • meltrin-alpha,
  • ADAM 12,
  • ADAM metallopeptidase domain 12,
  • EC 3.4.24.-,

View in BioMuta

Description…

ADAM12 is a member of the ADAM (a disintegrin and metalloprotease) protein family. ADAM family members are membrane-anchored proteins structurally related to snake venom disintegrins, and have been implicated in a variety of biological processes involving cell-cell and cell-matrix interactions. ADAM12 has two alternatively spliced transcripts: a shorter secreted form and a longer membrane-bound form. The shorter form is found to stimulate myogenesis.

Attributes

QA State: Curated
Type: Protein
Short Name:
HGNC Name: ADAM12

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Ovary

Attributes

Phase: Two
QA State: Under Review

Overview

ADAM12 is a transmembrane tumor vascular marker (TVM) that is selectively expressed in tumor vasculature and represents a promising target for vascular imaging or anti-vascular therapy of epithelial ovarian cancer.

Performance Comment

ADAM12 is very highly expressed in some epithelial ovarian cancer samples compared with normal ovaries but a significant number of cancer samples exhibited low levels of ADAM12. Thus, ADAM12 may hold predictive value, and it could be used for therapy, especially the long isoform, for patients whose tumors express it.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Announcement 10/07/2014

EDRN Patient Advocates will host an EDRN Advocacy Educational Webinar, Biomarkers for Prostate Cancer Detection and Monitoring, on Monday, January 12th, 2015, at 1 p.m. EDT / 10 a.m. PDT. Registration is not required for this. Please click for more information.
Announcement 09/14/2014

Thank you to everyone who helped make the 9th EDRN Scientific Workshop a success. We look forward to seeing everyone at the 28th EDRN Steering Committee Meeting from March 31-April 2, 2015, in Atlanta, GA.